source
- London biotech Oyster raises $60 million to develop tau-targeting protein degradersOyster Therapeutics, a London-based biotech, announced it has secured $60 million in an extension of its Series A financing round. The funding will support its lead program that uses a modified pr…
- PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trialPepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…